United States Oncology Clinical Trials Market is expected to reach USD 8.12 billion by 2032 | Major Companies - AstraZeneca, Merck & Co., Inc, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd.

Market Size and Growth:

The Global Oncology Clinical Trials Market size reached USD 17.1 billion in 2024 and is expected to reach USD 32.1 billion by 2032, growing with a CAGR of 8.3% during the forecast period 2025-2032.

The Oncology Clinical Trials Market refers to the global ecosystem involved in planning, conducting, managing, and analyzing clinical studies focused on cancer prevention, diagnosis, and treatment. It includes pharmaceutical and biotechnology companies, contract research organizations, research institutes, and regulatory bodies working across trial phases I-IV. The market is driven by rising cancer prevalence, advances in precision medicine and immunotherapy, increasing R&D investments, and the growing adoption of decentralized and adaptive trial designs worldwide.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/oncology-clinical-trials-market?sz

Recent Key Developments of United States:

✅ February 2026: Johnson & Johnson announced positive topline results from a combo immunotherapy trial in non-small cell lung cancer, with data submitted for priority review, boosting U.S. trial activity in immuno-oncology.

✅ January 2026: A Phase III trial for next-gen CAR-T therapy in hematologic cancers reported breakthrough overall response rates exceeding 80%, prompting expanded U.S. site activations. This development highlighted ongoing investments in cell therapies.

✅ December 2025: The NCI launched a decentralized trial platform for rare oncology indications, incorporating AI-driven patient matching to accelerate enrollment across multiple states. Early results indicated a 30% faster recruitment compared to traditional models.

✅ November 2025: FDA granted accelerated approval to a novel bispecific antibody for advanced solid tumors, marking a key advancement in Phase II trials led by major biotech firms. This approval stemmed from interim data showing improved progression-free survival rates in oncology patients.

Recent Key Developments of Japan:

✅ February 2026: A collaboration between Takeda and local CROs launched a multi-center trial for bispecific T-cell engagers in lymphoma, focusing on elderly patients amid Japan's aging demographic needs.

✅ January 2026: Astellas Pharma expanded a domestic trial for prostate cancer radiopharmaceuticals, incorporating real-world evidence to support Phase II bridging to U.S. data. Enrollment surged due to regulatory incentives for orphan indications.

✅ December 2025: The National Cancer Center Hospital initiated a Phase I study for a novel ADC in breast cancer, leveraging genomic profiling for patient selection and reporting promising safety data.

✅ November 2025: PMDA approved a fast-track designation for a targeted therapy trial in gastric cancer, enabling early Japanese patient inclusion in global studies. This aligned with efforts to integrate Japan into multinational oncology pipelines.

List of the Key Players in the Oncology Clinical Trials Market:

AstraZeneca
Merck & Co., Inc
Gilead Sciences, Inc
F. Hoffmann-La Roche Ltd
Syneos Health
Daiichi Sankyo Company
Eli Lilly and Company
PharmaMar
Novocure
Pfizer Inc

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/oncology-clinical-trials-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Oncology Clinical Trials Market:

By Phase Type: Phase I, Phase II, Phase III.

By Study Design: Interventional Studies, Observational Studies, Expanded access trials.

By Cancer Type: Lung Cancer, Breast Cancer, Prostrate Cancer, Skin Cancer, Others.

By End User: Biopharmaceutical Companies, Academic and Research Institutes, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=oncology-clinical-trials-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Oncology Clinical Trials market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Oncology Clinical Trials Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Oncology Clinical Trials market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Oncology Clinical Trials Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Oncology Clinical Trials Market in 2025?
◆ What is the projected growth rate of the Oncology Clinical Trials Market through 2033?
◆ Who are the key players in the Oncology Clinical Trials Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.